Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6,982 INR | -1.96% | -4.62% | +32.92% |
Apr. 12 | INDIA STOCKS-Financials drag Indian shares, hit by fading US rate cut hopes | RE |
Mar. 31 | Neuland Laboratories Limited Announces Resignation of P.V. Maiya as Director | CI |
Strengths
- Growth is a substantial asset for the company, as anticipated by dedicated analysts. Within the next three years, growth is estimated to reach 64% by 2026.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For several months, analysts have been revising their EPS estimates roughly upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 29.56 times its estimated earnings per share for the ongoing year.
- The company is highly valued given the cash flows generated by its activity.
- The company is not the most generous with respect to shareholders' compensation.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+32.92% | 1.1B | - | ||
+24.17% | 556B | B | ||
-6.33% | 354B | C+ | ||
+19.90% | 331B | B- | ||
+7.95% | 296B | C+ | ||
+13.45% | 233B | B+ | ||
+6.04% | 201B | B- | ||
-10.51% | 193B | A+ | ||
-12.26% | 143B | C+ | ||
-6.47% | 144B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- NEULANDLAB Stock
- Ratings Neuland Laboratories Limited